Global Natural Killer Cells Therapeutics Market

Natural Killer Cells Therapeutics Comprehensive Study by Type (NK Cell Therapies, NK Cell Directed Antibodies), Application (Research Centers & Institutes, Hospitals, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), End User (Research Centers & Institutes, Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2030

Natural Killer Cells Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Natural Killer Cells Therapeutics
Natural Killer Cells Therapeutics are significantly used in the medical services division, attributable to increment in the predominance of infections, including malignant growth, gastrointestinal ailments, and others. Additionally, ascend in government consumption in the medical services part and increment in the consciousness of immunotherapy to treat different infections are foreseen to support market development. Moreover, progressing R&D exercises in disease immunotherapy to give progressed highlights to patients for powerful treatment fundamentally fuel the market development

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Global natural killer cell therapeutics market is highly split and the main players have used a range of strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Natural Killer Cells Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Affimed GmbH (Germany), Celgene Corporation (United States), Fate Therapeutics (United States), Fortress Biotech, Inc. (United States), Glycostem Therapeutics B.V.(Netherlands, Innate Pharma S.A. (France), Nantkwest Inc. (United States), Nkarta Therapeutics, Inc. (United States), NKT Therapeutics Inc.(United States) and Ziopharm Oncology Inc (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Kiadis Pharma (Netherlands), Phio Pharmaceuticals Corporation (United States), Glycostem Therapeutics (Netherlands), EMERCell (France), Brink Biologics, Inc (United States) and Cytovia Therapeutics Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Natural Killer Cells Therapeutics market by Type (NK Cell Therapies and NK Cell Directed Antibodies), Application (Research Centers & Institutes, Hospitals and Others) and Region.



On the basis of geography, the market of Natural Killer Cells Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Natural Killer Cells Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Research Centers & Institutes will boost the Natural Killer Cells Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Growing adoption of Natural Killer Cells Therapeutics for cancer and infectious diseases treatment will increase the market size and Augmentin incidence of cancer across the globe is another key driving factor of growth

Challenges:
Stringent government regulations toward approval of Treatment

Restraints:
The high cost of cancer Associated with treatment

Opportunities:
The surge in R&D activities toward the development of immunotherapy is creating the growth opportunities

Market Leaders and their expansionary development strategies
In March 2019, Phio Therapeutics Corp. and Glycostem proclaim a research partnership for the development of a combination of sd-rxRNA, Phio’s RNAi technology, and oNKord, Glycostem’s NK-Cell generation technology for the treatment of cancer
In December , 2022 Sanofi and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Natural Killer Cells Therapeutics Providers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • NK Cell Therapies
  • NK Cell Directed Antibodies
By Application
  • Research Centers & Institutes
  • Hospitals
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By End User
  • Research Centers & Institutes
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing adoption of Natural Killer Cells Therapeutics for cancer and infectious diseases treatment will increase the market size
      • 3.2.2. Augmentin incidence of cancer across the globe is another key driving factor of growth
    • 3.3. Market Challenges
      • 3.3.1. Stringent government regulations toward approval of Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Natural Killer Cells Therapeutics, by Type, Application, Distribution Channel, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Natural Killer Cells Therapeutics (Value)
      • 5.2.1. Global Natural Killer Cells Therapeutics by: Type (Value)
        • 5.2.1.1. NK Cell Therapies
        • 5.2.1.2. NK Cell Directed Antibodies
      • 5.2.2. Global Natural Killer Cells Therapeutics by: Application (Value)
        • 5.2.2.1. Research Centers & Institutes
        • 5.2.2.2. Hospitals
        • 5.2.2.3. Others
      • 5.2.3. Global Natural Killer Cells Therapeutics by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Pharmacy
        • 5.2.3.3. Retail Pharmacy
        • 5.2.3.4. Others
      • 5.2.4. Global Natural Killer Cells Therapeutics by: End User (Value)
        • 5.2.4.1. Research Centers & Institutes
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Homecare
        • 5.2.4.4. Specialty Clinics
        • 5.2.4.5. Others
      • 5.2.5. Global Natural Killer Cells Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Natural Killer Cells Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Affimed GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fate Therapeutics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Fortress Biotech, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Glycostem Therapeutics B.V.(Netherlands
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Innate Pharma S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nantkwest Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nkarta Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NKT Therapeutics Inc.(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ziopharm Oncology Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Natural Killer Cells Therapeutics Sale, by Type, Application, Distribution Channel, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Natural Killer Cells Therapeutics (Value)
      • 7.2.1. Global Natural Killer Cells Therapeutics by: Type (Value)
        • 7.2.1.1. NK Cell Therapies
        • 7.2.1.2. NK Cell Directed Antibodies
      • 7.2.2. Global Natural Killer Cells Therapeutics by: Application (Value)
        • 7.2.2.1. Research Centers & Institutes
        • 7.2.2.2. Hospitals
        • 7.2.2.3. Others
      • 7.2.3. Global Natural Killer Cells Therapeutics by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Pharmacy
        • 7.2.3.3. Retail Pharmacy
        • 7.2.3.4. Others
      • 7.2.4. Global Natural Killer Cells Therapeutics by: End User (Value)
        • 7.2.4.1. Research Centers & Institutes
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Homecare
        • 7.2.4.4. Specialty Clinics
        • 7.2.4.5. Others
      • 7.2.5. Global Natural Killer Cells Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Natural Killer Cells Therapeutics: by Type(USD Million)
  • Table 2. Natural Killer Cells Therapeutics NK Cell Therapies , by Region USD Million (2018-2023)
  • Table 3. Natural Killer Cells Therapeutics NK Cell Directed Antibodies , by Region USD Million (2018-2023)
  • Table 4. Natural Killer Cells Therapeutics: by Application(USD Million)
  • Table 5. Natural Killer Cells Therapeutics Research Centers & Institutes , by Region USD Million (2018-2023)
  • Table 6. Natural Killer Cells Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 7. Natural Killer Cells Therapeutics Others , by Region USD Million (2018-2023)
  • Table 8. Natural Killer Cells Therapeutics: by Distribution Channel(USD Million)
  • Table 9. Natural Killer Cells Therapeutics Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Natural Killer Cells Therapeutics Online Pharmacy , by Region USD Million (2018-2023)
  • Table 11. Natural Killer Cells Therapeutics Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Natural Killer Cells Therapeutics Others , by Region USD Million (2018-2023)
  • Table 13. Natural Killer Cells Therapeutics: by End User(USD Million)
  • Table 14. Natural Killer Cells Therapeutics Research Centers & Institutes , by Region USD Million (2018-2023)
  • Table 15. Natural Killer Cells Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 16. Natural Killer Cells Therapeutics Homecare , by Region USD Million (2018-2023)
  • Table 17. Natural Killer Cells Therapeutics Specialty Clinics , by Region USD Million (2018-2023)
  • Table 18. Natural Killer Cells Therapeutics Others , by Region USD Million (2018-2023)
  • Table 19. South America Natural Killer Cells Therapeutics, by Country USD Million (2018-2023)
  • Table 20. South America Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 21. South America Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 22. South America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 23. South America Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 24. Brazil Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 25. Brazil Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 26. Brazil Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 27. Brazil Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 28. Argentina Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 29. Argentina Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 30. Argentina Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 31. Argentina Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 32. Rest of South America Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 36. Asia Pacific Natural Killer Cells Therapeutics, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 40. Asia Pacific Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 41. China Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 42. China Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 43. China Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 44. China Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 45. Japan Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 46. Japan Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 47. Japan Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 48. Japan Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 49. India Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 50. India Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 51. India Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 52. India Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 53. South Korea Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 54. South Korea Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 55. South Korea Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 56. South Korea Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 57. Taiwan Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 58. Taiwan Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 59. Taiwan Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 60. Taiwan Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 61. Australia Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 62. Australia Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 63. Australia Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 64. Australia Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 69. Europe Natural Killer Cells Therapeutics, by Country USD Million (2018-2023)
  • Table 70. Europe Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 71. Europe Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 72. Europe Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 73. Europe Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 74. Germany Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 75. Germany Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 76. Germany Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 77. Germany Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 78. France Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 79. France Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 80. France Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 81. France Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 82. Italy Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 83. Italy Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 84. Italy Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 85. Italy Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 86. United Kingdom Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 89. United Kingdom Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 90. Netherlands Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 91. Netherlands Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 92. Netherlands Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 93. Netherlands Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 94. Rest of Europe Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 98. MEA Natural Killer Cells Therapeutics, by Country USD Million (2018-2023)
  • Table 99. MEA Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 100. MEA Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 101. MEA Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 102. MEA Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 103. Middle East Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 104. Middle East Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 105. Middle East Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 106. Middle East Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 107. Africa Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 108. Africa Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 109. Africa Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 110. Africa Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 111. North America Natural Killer Cells Therapeutics, by Country USD Million (2018-2023)
  • Table 112. North America Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 113. North America Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 114. North America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 115. North America Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 116. United States Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 117. United States Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 118. United States Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 119. United States Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 120. Canada Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 121. Canada Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 122. Canada Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 123. Canada Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 124. Mexico Natural Killer Cells Therapeutics, by Type USD Million (2018-2023)
  • Table 125. Mexico Natural Killer Cells Therapeutics, by Application USD Million (2018-2023)
  • Table 126. Mexico Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 127. Mexico Natural Killer Cells Therapeutics, by End User USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Natural Killer Cells Therapeutics: by Type(USD Million)
  • Table 139. Natural Killer Cells Therapeutics NK Cell Therapies , by Region USD Million (2025-2030)
  • Table 140. Natural Killer Cells Therapeutics NK Cell Directed Antibodies , by Region USD Million (2025-2030)
  • Table 141. Natural Killer Cells Therapeutics: by Application(USD Million)
  • Table 142. Natural Killer Cells Therapeutics Research Centers & Institutes , by Region USD Million (2025-2030)
  • Table 143. Natural Killer Cells Therapeutics Hospitals , by Region USD Million (2025-2030)
  • Table 144. Natural Killer Cells Therapeutics Others , by Region USD Million (2025-2030)
  • Table 145. Natural Killer Cells Therapeutics: by Distribution Channel(USD Million)
  • Table 146. Natural Killer Cells Therapeutics Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 147. Natural Killer Cells Therapeutics Online Pharmacy , by Region USD Million (2025-2030)
  • Table 148. Natural Killer Cells Therapeutics Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 149. Natural Killer Cells Therapeutics Others , by Region USD Million (2025-2030)
  • Table 150. Natural Killer Cells Therapeutics: by End User(USD Million)
  • Table 151. Natural Killer Cells Therapeutics Research Centers & Institutes , by Region USD Million (2025-2030)
  • Table 152. Natural Killer Cells Therapeutics Hospitals , by Region USD Million (2025-2030)
  • Table 153. Natural Killer Cells Therapeutics Homecare , by Region USD Million (2025-2030)
  • Table 154. Natural Killer Cells Therapeutics Specialty Clinics , by Region USD Million (2025-2030)
  • Table 155. Natural Killer Cells Therapeutics Others , by Region USD Million (2025-2030)
  • Table 156. South America Natural Killer Cells Therapeutics, by Country USD Million (2025-2030)
  • Table 157. South America Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 158. South America Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 159. South America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 160. South America Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 161. Brazil Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 162. Brazil Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 163. Brazil Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 164. Brazil Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 165. Argentina Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 166. Argentina Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 167. Argentina Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 168. Argentina Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 169. Rest of South America Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 170. Rest of South America Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 171. Rest of South America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 172. Rest of South America Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 173. Asia Pacific Natural Killer Cells Therapeutics, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 175. Asia Pacific Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 176. Asia Pacific Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 177. Asia Pacific Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 178. China Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 179. China Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 180. China Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 181. China Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 182. Japan Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 183. Japan Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 184. Japan Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 185. Japan Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 186. India Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 187. India Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 188. India Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 189. India Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 190. South Korea Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 191. South Korea Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 192. South Korea Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 193. South Korea Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 194. Taiwan Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 195. Taiwan Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 196. Taiwan Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 197. Taiwan Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 198. Australia Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 199. Australia Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 200. Australia Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 201. Australia Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 206. Europe Natural Killer Cells Therapeutics, by Country USD Million (2025-2030)
  • Table 207. Europe Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 208. Europe Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 209. Europe Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 210. Europe Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 211. Germany Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 212. Germany Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 213. Germany Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 214. Germany Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 215. France Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 216. France Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 217. France Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 218. France Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 219. Italy Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 220. Italy Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 221. Italy Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 222. Italy Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 223. United Kingdom Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 224. United Kingdom Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 225. United Kingdom Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 226. United Kingdom Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 227. Netherlands Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 228. Netherlands Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 229. Netherlands Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 230. Netherlands Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 231. Rest of Europe Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 232. Rest of Europe Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 233. Rest of Europe Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 234. Rest of Europe Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 235. MEA Natural Killer Cells Therapeutics, by Country USD Million (2025-2030)
  • Table 236. MEA Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 237. MEA Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 238. MEA Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 239. MEA Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 240. Middle East Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 241. Middle East Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 242. Middle East Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 243. Middle East Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 244. Africa Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 245. Africa Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 246. Africa Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 247. Africa Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 248. North America Natural Killer Cells Therapeutics, by Country USD Million (2025-2030)
  • Table 249. North America Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 250. North America Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 251. North America Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 252. North America Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 253. United States Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 254. United States Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 255. United States Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 256. United States Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 257. Canada Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 258. Canada Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 259. Canada Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 260. Canada Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 261. Mexico Natural Killer Cells Therapeutics, by Type USD Million (2025-2030)
  • Table 262. Mexico Natural Killer Cells Therapeutics, by Application USD Million (2025-2030)
  • Table 263. Mexico Natural Killer Cells Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 264. Mexico Natural Killer Cells Therapeutics, by End User USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Natural Killer Cells Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Natural Killer Cells Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Natural Killer Cells Therapeutics: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Natural Killer Cells Therapeutics: by End User USD Million (2018-2023)
  • Figure 8. South America Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 10. Europe Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 11. MEA Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 12. North America Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 13. Global Natural Killer Cells Therapeutics share by Players 2023 (%)
  • Figure 14. Global Natural Killer Cells Therapeutics share by Players (Top 3) 2023(%)
  • Figure 15. Global Natural Killer Cells Therapeutics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Affimed GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Affimed GmbH (Germany) Revenue: by Geography 2023
  • Figure 19. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 21. Fate Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 22. Fate Therapeutics (United States) Revenue: by Geography 2023
  • Figure 23. Fortress Biotech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Fortress Biotech, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Glycostem Therapeutics B.V.(Netherlands Revenue, Net Income and Gross profit
  • Figure 26. Glycostem Therapeutics B.V.(Netherlands Revenue: by Geography 2023
  • Figure 27. Innate Pharma S.A. (France) Revenue, Net Income and Gross profit
  • Figure 28. Innate Pharma S.A. (France) Revenue: by Geography 2023
  • Figure 29. Nantkwest Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Nantkwest Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Nkarta Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Nkarta Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. NKT Therapeutics Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 34. NKT Therapeutics Inc.(United States) Revenue: by Geography 2023
  • Figure 35. Ziopharm Oncology Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Ziopharm Oncology Inc (United States) Revenue: by Geography 2023
  • Figure 37. Global Natural Killer Cells Therapeutics: by Type USD Million (2025-2030)
  • Figure 38. Global Natural Killer Cells Therapeutics: by Application USD Million (2025-2030)
  • Figure 39. Global Natural Killer Cells Therapeutics: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Natural Killer Cells Therapeutics: by End User USD Million (2025-2030)
  • Figure 41. South America Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 43. Europe Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 44. MEA Natural Killer Cells Therapeutics Share (%), by Country
  • Figure 45. North America Natural Killer Cells Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Affimed GmbH (Germany)
  • Celgene Corporation (United States)
  • Fate Therapeutics (United States)
  • Fortress Biotech, Inc. (United States)
  • Glycostem Therapeutics B.V.(Netherlands
  • Innate Pharma S.A. (France)
  • Nantkwest Inc. (United States)
  • Nkarta Therapeutics, Inc. (United States)
  • NKT Therapeutics Inc.(United States)
  • Ziopharm Oncology Inc (United States)
Additional players considered in the study are as follows:
Kiadis Pharma (Netherlands) , Phio Pharmaceuticals Corporation (United States) , Glycostem Therapeutics (Netherlands) , EMERCell (France) , Brink Biologics, Inc (United States) , Cytovia Therapeutics Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 225 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Natural Killer Cells Therapeutics Market Quantitative research analysis
Global Natural Killer Cells Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Affimed GmbH (Germany), Celgene Corporation (United States), Fate Therapeutics (United States), Fortress Biotech, Inc. (United States), Glycostem Therapeutics B.V.(Netherlands, Innate Pharma S.A. (France), Nantkwest Inc. (United States), Nkarta Therapeutics, Inc. (United States), NKT Therapeutics Inc.(United States) and Ziopharm Oncology Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Natural Killer Cells Therapeutics Market during projected period 2023-2030.
The Natural Killer Cells Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Natural Killer Cells Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Mercaptopurine Comprehensive Study by Application (Leukemia, acute lymphoid Lymphoma, Non-Hodgkin’s Leukemia, Acute Myelogenous Leukemia, Chronic Myeloid), Form (Oral Suspension, Injection, Tablet, L...
$ 3650
Immunity Nutraceutical Ingredient Comprehensive Study by Type (Phytochemical and plant extracts, Omega-3 fatty acids, Minerals, Fibers & specialty carbohydrates, Carotenoids, Other Types), Applicatio...
$ 3750
Arrhythmia Monitoring Devices Comprehensive Study by Application (Hospitals & Clinics, Diagnostic Centres, Ambulatory Surgical Centers, Homecare Settings), Distribution Channel (Online Stores, Offlin...
$ 3450
Aspartame Free Gum Comprehensive Study by Type (Stick Gum, Tab Gum), Polyol Type (Erythritol, Xylitol, Others), Sales Channel (Online Sales, Offline Sales) Players and Region - Global Market Outlook ...
$ 3500
Pregnancy Care Product Comprehensive Study by Type (Stretch Mark Minimizer, Breast Cream, Toning/Firming Lotion, Itching Prevention Cream, Nipple Protection Cream, Others), Distribution Channel (Hosp...
$ 3800
Dental Carpule Comprehensive Study by Distribution Channel (Online Channel, Offline Channel), End-user (Hospitals, Dental Clinics, Home Care, Others), Age Group (Children, Adults), Material (Glass, P...
$ 3500